 - Patients may present with advanced disease KS andor concurrent KSHV-associated multicentric Castleman disease MCD or an IL-6 related KSHV-associated cytokine syndrome KICS. Patients with the latter conditions have poor outcomes when treated with FDA-approved cytotoxic therapies used for KS, and novel approaches are needed. 